Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine

Dialysis and kidney transplant patients are vulnerable populations for COVID-19 related disease and mortality. We conducted a prospective study exploring the eight week time course of specific cellular (interferon-γ release assay and flow cytometry) or/and humoral immune responses (ELISA) to SARS-Co...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet regional health. Europe 2021-10, Vol.9, p.100178, Article 100178
Main Authors: Stumpf, Julian, Siepmann, Torsten, Lindner, Tom, Karger, Claudia, Schwöbel, Jörg, Anders, Leona, Faulhaber-Walter, Robert, Schewe, Jens, Martin, Heike, Schirutschke, Holger, Barnett, Kerstin, Hüther, Jan, Müller, Petra, Langer, Torsten, Pluntke, Thilo, Anding-Rost, Kirsten, Meistring, Frank, Stehr, Thomas, Pietzonka, Annegret, Escher, Katja, Cerny, Simon, Rothe, Hansjörg, Pistrosch, Frank, Seidel, Harald, Paliege, Alexander, Beige, Joachim, Bast, Ingolf, Steglich, Anne, Gembardt, Florian, Kessel, Friederike, Kröger, Hannah, Arndt, Patrick, Sradnick, Jan, Frank, Kerstin, Klimova, Anna, Mauer, René, Grählert, Xina, Anft, Moritz, Blazquez-Navarro, Arturo, Westhoff, Timm H, Stervbo, Ulrik, Tonn, Torsten, Babel, Nina, Hugo, Christian
Format: Article
Language:English
Subjects:
BNT162b2
clinical decision-making
COVID-19
dialysis patients
epidemiology
guidelines
humoral and cellular immune response
kidney transplant recipients
medical personnel
mRNA-1273
Research Paper
SARS-CoV-2 vaccination
tozinameran
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dialysis and kidney transplant patients are vulnerable populations for COVID-19 related disease and mortality. We conducted a prospective study exploring the eight week time course of specific cellular (interferon-γ release assay and flow cytometry) or/and humoral immune responses (ELISA) to SARS-CoV-2 boost vaccination in more than 3100 participants including medical personnel, dialysis patients and kidney transplant recipients using mRNA vaccines BNT162b2 or mRNA-1273. SARS-CoV-2-vaccination induced seroconversion efficacy in dialysis patients was similar to medical personnel (> 95%), but markedly impaired in kidney transplant recipients (42%). T-cellular immunity largely mimicked humoral results. Major risk factors of seroconversion failure were immunosuppressive drug number and type (belatacept, MMF-MPA, calcineurin-inhibitors) as well as vaccine type (BNT162b2 mRNA). Seroconversion rates induced by mRNA-1273 compared to BNT162b2 vaccine were 97% to 88% (p 
ISSN:2666-7762
2666-7762
DOI:10.1016/j.lanepe.2021.100178